Increase in isolation of extended spectrum beta lactamase producing multidrug resistant non typhoidal Salmonellae in Pakistan.
BACKGROUND
Increasing resistance to quinolones and ceftriaxone in non typhoidal Salmonellae is a global concern. Resistance to quinolone and 3rd generation cephalosporin amongst non typhoidal Salmonellae (NTS) from Pakistan has been reported in this study.


METHODS
Retrospective analysis of laboratory data was conducted (1990-2006). NTS were isolated and identified from clinical samples using standard microbiological techniques. Antimicrobial susceptibility testing was performed by Kirby Bauer. Extended spectrum beta lactamase production (ESBL) was detected using combined disc method. Ciprofloxacin sensitivity was detected by nalidixic acid screening method. Minimum inhibitory concentration (MIC) of ciprofloxacin was determined by agar dilution method. Statistical analysis was performed using SPSS version 13.


RESULTS
Analysis of 1967 NTS isolates showed a significant increase in ciprofloxacin resistance from 23% in 2002 to 50.5% in 2006, with increased mean MIC values from 0.6 to 1.3 ug/mL. Ceftriaxone resistant NTS also increased and ESBL production was seen in 98.7% isolates. These isolates exhibited high resistance against amoxicillin clavulanic acid (57%), gentamicin (69%), amikacin (44%) and piperacillin tazobactam (30%). No resistance to carbapenem was seen. Ceftriaxone resistance was significantly higher in children <1 year, in invasive isolates and in Salmonella Typhimurium.


CONCLUSIONS
Increase in quinolone and ceftriaxone NTS is a serious threat to public health requiring continuous surveillance and use of appropriate screening tests for laboratory detection.
Jabeen
Kauser
K
Department of Pathology and Microbiology, Aga Khan University, Karachi, Pakistan. kausar.jabeen@aku.edu
Zafar
Afia
A
Irfan
Seema
S
Khan
Erum
E
Mehraj
Vikram
V
Hasan
Rumina
R
D001426:Bacterial Proteins / Q000096:biosynthesis*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D010154:Pakistan / Q000453:epidemiology; D015995:Prevalence; D012189:Retrospective Studies; D012475:Salmonella / Q000201:enzymology* / Q000302:isolation & purification; D012480:Salmonella Infections / Q000453:epidemiology* / Q000382:microbiology*; D001618:beta-Lactamases / Q000096:biosynthesis*
D001426:Bacterial Proteins; D001618:beta-Lactamases
Microb Drug Resist. 1997 Fall;3(3):263-6
9270996
J Infect Dis. 2004 Nov 1;190(9):1652-4
15478071
Clin Infect Dis. 2001 Jan 15;32(2):263-9
11170916
J Antimicrob Chemother. 2000 Nov;46(5):860-2
11062222
J Antimicrob Chemother. 2001 Mar;47(3):315-21
11222564
J Antimicrob Chemother. 2005 Jul;56(1):110-4
15914492
J Clin Microbiol. 2005 Jul;43(7):3237-43
16000441
Int J Antimicrob Agents. 2006 Sep;28(3):166-71
16904874
J Clin Microbiol. 1999 Nov;37(11):3572-7
10523554
Antimicrob Agents Chemother. 2003 Apr;47(4):1297-300
12654661
Clin Infect Dis. 2004 Aug 15;39(4):546-51
15356819
Emerg Infect Dis. 2002 May;8(5):490-5
11996684
J Antimicrob Chemother. 2005 Aug;56(2):262-4
16000403
Lancet Infect Dis. 2005 Aug;5(8):481-93
16048717
N Engl J Med. 1999 Nov 4;341(19):1420-5
10547404
Emerg Infect Dis. 1999 Sep-Oct;5(5):607-25
10511517